Qvirus announced the release of its customized AAV testing services to accelerate the research of viral vaccine and gene therapy.
Shirley, USA - December 16, 2021 /MarketersMEDIA/ —
Qvirus platform, the mature division of Creative Biogene, a scientists-driven biotechnology company whose mission focuses on developing high quality reagents and professional services that can help researchers explore questions about gene discovery and function. With innovative technologies and unique tools, Qvirus is dedicated to accelerating the development in the areas of biological and biomedical research. Recently, Qvirus announced the release of its customized AAV testing services to accelerate the research of viral vaccine and gene therapy.
From the creation of the main cell bank to batch release, QVirus Platform provides customers with a comprehensive GMP, GLP and USP testing service portfolio to support customers' pipelines based on AAV procedures. With decades of virology experience, a team of expert scientists, and continuous investment in equipment and facilities, QVirus Platform provides an AAV-based testing platform for product purity and safety.
Qvirus Platform’s AAV test plan also includes the use of established detection methods to quantify genome/vector copy numbers, covering common sequences of multiple AAV serotypes, experience in genomic titer determination by qPCR or ddPCR, and cell-based titer analysis of AAV and other viral vectors.
With many years of professional experience in the virus field, QVirus Platform can provide the most affordable and high-quality AAV empty capsid detection service during the rAAV production process. In order to detect and quantify the endotoxin levels in rAAV products, QVirus Platform has developed a variety of technologies to determine the ratio of these empty or partially filled capsids to intact AAV, such as analysis of ultracentrifugation (AUC), transmission electron microscopy (TEM) Wait.
In order to detect and quantify the vector genome titer in rAAV products, Qvirus Platform can use quantitative real-time PCR (qPCR) and droplet digital PCR (ddPCR) methods. As the most widely used method for quantifying the genome of packaged AAV vectors, qPCR analysis usually uses a calibration curve prepared with plasmid DNA as a reference. However, Qvirus Platform can use AAV reference materials as qPCR standards instead of plasmid DNA.
QVirus Platform has developed solutions for customers to titrate infectious AAV vector particles, including median tissue culture infectious dose (TCID50) determination and infection center determination (ICA) to facilitate experimental design and reproducibility of results. In order to detect and quantify the endotoxin levels in rAAV products, Qvirus Platform can use limulus amebocyte lysate (LAL) and rabbit pyrogen detection methods to evaluate the purity, efficacy and safety of viral vaccines or gene therapy products at the appropriate stage.
“Based on our continuous exploration and leading technology, QVirus platform has established a variety of strategies and resources to assist in various fields of viral vector design, construction and verification, as well as the generation of high-titer viruses for research.” said Marcia Brady, the marketing director of Creative Biogene, she also claimed, “Our expertise in virology has made us a leader in the industry, supporting the development and GMP manufacturing of viral vaccines, gene therapies and other virus-based technologies for customers around the world.”
About Qvirus Platform
Qvirus Platform, as a division of Creative Biogene, provides world-class packaging services for a variety of virus vector products. The expertise and years of experience have made Qvirus platform become a well-recognized industry leader in supporting the development of gene therapy and scientists worldwide.
Contact Info:
Name: Marcia Brady
Email: Send Email
Organization: Creative Biogene
Address: Shirley, NY 11967, USA
Phone: 6313868241
Website: https://qvirus.creative-biogene.com/
Source: MarketersMEDIA
Release ID: 89056951
